The role of pasireotide in the treatment of acromegaly

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 11, 2014, Pages 855-856

  Tritos, Nicholas A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; LONG ACTING DRUG; PASIREOTIDE; CYCLOPEPTIDE; OCTREOTIDE; SOMATOSTATIN;

ACROMEGALY; ACUTE DRUG ADMINISTRATION; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; GROWTH HORMONE RELEASE; HIGH RISK PATIENT; HORMONE INHIBITION; HUMAN; HYPERGLYCEMIA; NOTE; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; FEMALE; MALE;

ACROMEGALY; FEMALE; HUMANS; MALE; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 84922516114     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70175-5     Document Type: Note

References (10)

1. Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 2014, 10:243-248.
2. Swearingen B Update on pituitary surgery. J Clin Endocrinol Metab 2012, 97:1073-1081.
3. Loeffler JS, Shih HA Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011, 96:1992-2003.
4. Andersen M Management of endocrine disease: GH excess: diagnosis and medical therapy. Eur J Endocrinol 2014, 170:R31-R41.
5. van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004, 89:638-645.
6. Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2014, on behalf of the Pasireotide C2402 Study Group, published online Sept 24. http://dx.doi.org/10.1016/S2213-8587(14)70169-X.
7. Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014, 99:791-799.
8. Gadelha MR, Kasuki L, Korbonits M Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 2013, 24:238-246.
9. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013, 98:3446-3453.
10. Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary 2014, 17:180-186.